These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1657 related articles for article (PubMed ID: 25898198)

  • 1. IL-6 as a keystone cytokine in health and disease.
    Hunter CA; Jones SA
    Nat Immunol; 2015 May; 16(5):448-57. PubMed ID: 25898198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-19 is a negative regulator of innate immunity and critical for colonic protection.
    Azuma YT; Matsuo Y; Nakajima H; Yancopoulos GD; Valenzuela DM; Murphy AJ; Karow M; Takeuchi T
    J Pharmacol Sci; 2011; 115(2):105-11. PubMed ID: 21157117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific targeting of IL-6 signalling pathway: a new way to treat IBD?
    Desreumaux P
    Gut; 2000 Oct; 47(4):465-6. PubMed ID: 10986204
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target.
    Allocca M; Jovani M; Fiorino G; Schreiber S; Danese S
    Curr Drug Targets; 2013 Nov; 14(12):1508-21. PubMed ID: 24102406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
    Rose-John S; Mitsuyama K; Matsumoto S; Thaiss WM; Scheller J
    Curr Pharm Des; 2009; 15(18):2095-103. PubMed ID: 19519447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innate immune signals in autoimmune and autoinflammatory uveitis.
    Rosenbaum JT; Kim HW
    Int Rev Immunol; 2013 Feb; 32(1):68-75. PubMed ID: 23360159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis.
    Rath T; Billmeier U; Waldner MJ; Atreya R; Neurath MF
    Arch Toxicol; 2015 Apr; 89(4):541-54. PubMed ID: 25632846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
    Sfikakis PP
    Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application.
    Ariza ME; Williams MV; Wong HK
    Clin Immunol; 2013 Feb; 146(2):131-9. PubMed ID: 23314273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subclinical gut inflammation in ankylosing spondylitis.
    Ciccia F; Rizzo A; Triolo G
    Curr Opin Rheumatol; 2016 Jan; 28(1):89-96. PubMed ID: 26599385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment.
    Jethwa H; Bowness P
    Clin Exp Immunol; 2016 Jan; 183(1):30-6. PubMed ID: 26080615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small dense LDL cholesterol in human subjects with different chronic inflammatory diseases.
    Schulte DM; Paulsen K; Türk K; Brandt B; Freitag-Wolf S; Hagen I; Zeuner R; Schröder JO; Lieb W; Franke A; Nikolaus S; Mrowietz U; Gerdes S; Schreiber S; Laudes M
    Nutr Metab Cardiovasc Dis; 2018 Nov; 28(11):1100-1105. PubMed ID: 30143407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between interleukin 10 and interleukin 6 in human B-cell differentiation.
    Bönig H; Packeisen J; Röhne B; Hempel L; Hannen M; Klein-Vehne A; Burdach S; Körholz D
    Immunol Invest; 1998; 27(4-5):267-80. PubMed ID: 9730087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
    Ohsugi Y
    Biol Pharm Bull; 2007 Nov; 30(11):2001-6. PubMed ID: 17978466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-10-overexpressing B cells regulate innate and adaptive immune responses.
    Stanic B; van de Veen W; Wirz OF; Rückert B; Morita H; Söllner S; Akdis CA; Akdis M
    J Allergy Clin Immunol; 2015 Mar; 135(3):771-80.e8. PubMed ID: 25240783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biology behind interleukin-6 targeted interventions.
    Liu X; Jones GW; Choy EH; Jones SA
    Curr Opin Rheumatol; 2016 Mar; 28(2):152-60. PubMed ID: 26751841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-27 mediates inflammation during chronic disease.
    Wynick C; Petes C; Gee K
    J Interferon Cytokine Res; 2014 Oct; 34(10):741-9. PubMed ID: 24797503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-6: designing specific therapeutics for a complex cytokine.
    Garbers C; Heink S; Korn T; Rose-John S
    Nat Rev Drug Discov; 2018 Jun; 17(6):395-412. PubMed ID: 29725131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interleukin-6 From molecular mechanisms of signal transduction to physiological properties and therapeutic targeting].
    Drutskaya MS; Nosenko MA; Atretkhany KS; Efimov GA; Nedospasov SA
    Mol Biol (Mosk); 2015; 49(6):937-43. PubMed ID: 26710772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade.
    Schurich A; Raine C; Morris V; Ciurtin C
    Rheumatology (Oxford); 2018 Feb; 57(2):246-254. PubMed ID: 28541488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 83.